Trimethylaminuria, often called fish odor syndrome, is a metabolic condition in which the body cannot fully break down trimethylamine, a pungent compound produced during the digestion of certain foods. The result is a persistent fishy smell released through sweat, breath, and urine. It is caused by reduced activity of a liver enzyme called FMO3, most often because of inherited genetic mutations, though hormonal shifts and other factors can also play a role.
Where the Smell Comes From
When you eat foods containing choline, carnitine, or certain other nutrients, gut bacteria break those compounds down and produce trimethylamine, or TMA. TMA itself smells strongly of rotting fish. Normally, after TMA is absorbed from the intestine into the bloodstream, a liver enzyme called FMO3 converts it into a non-smelling molecule called TMAO, which is then flushed out in urine.1PubMed Central. Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease In people with trimethylaminuria, FMO3 does not work well enough to handle the TMA load. The unconverted TMA accumulates and escapes through every available exit: urine, sweat, saliva, and exhaled breath.
FMO3 is remarkably specific. Among all the enzyme forms in the human body that could theoretically oxidize TMA, FMO3 is by far the most active, operating at roughly thirty times the rate of any other candidate enzyme. Only adult liver tissue shows substantial TMA-processing ability; fetal liver, kidney, and intestinal tissue barely register.2PubMed. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3 That means there is essentially no backup system. If FMO3 falters, TMA has nowhere else to go.
Genetics and Inheritance
The most common form of trimethylaminuria is inherited in an autosomal recessive pattern. Both parents carry a mutated copy of the FMO3 gene without showing symptoms themselves, and a child who receives two faulty copies ends up with severely reduced enzyme activity.3Pharmacogenetics and Genomics. A novel mutation in the flavin-containing monooxygenase 3 gene, FMO3, that causes fish-odour syndrome: activity of the mutant enzyme assessed by proton NMR spectroscopy Dozens of different mutations in FMO3 have been catalogued, spread across a wide range of haplotypes. One study that screened affected patients found 17 distinct variants distributed across 26 different haplotype combinations, with both nonsense and missense mutations reducing how efficiently the enzyme grabs and processes TMA.4PubMed Central. Adaptive Modelling of Mutated FMO3 Enzyme Could Unveil Unexplored Scenarios Linking Variant Haplotypes to TMAU Phenotypes
Not all of these mutations are equally severe. Some wipe out enzyme function almost completely, while others leave a person with a milder or intermittent form that only flares under certain conditions. Two common polymorphisms, known informally by their amino acid changes at positions 158 and 308, are found in a substantial proportion of the global population. The compound variant combining both changes was found in roughly 12 to 38 percent of non-African populations sampled across Europe and East Asia, but appeared in only about 1.3 percent of African populations.5PubMed. Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis Carriers of these common variants usually do not have the full-blown syndrome, but under the right circumstances their FMO3 capacity can dip low enough to produce noticeable odor, especially in combination with other triggers.
Why Symptoms Come and Go
One of the most frustrating features of trimethylaminuria is its unpredictability. Many people with the condition report that the smell worsens dramatically at certain times and nearly vanishes at others. Several factors explain this variability.
Diet is the most direct trigger. Foods rich in choline (eggs, liver, soybeans, some legumes), carnitine (red meat), and trimethylamine itself (certain saltwater fish) flood the gut with raw material for TMA production. Cut those foods and TMA production drops; eat a large serving and it spikes. Gut bacteria also respond to dietary fat composition. Saturated long-chain fatty acids promote conditions in the colon that favor TMA-producing bacteria, potentially increasing TMA output even when choline intake stays the same.6PubMed Central. Dietary Fatty Acids Modulate Gut Microbiota-Derived Trimethylamine-N-Oxide: Potential Mechanisms and Future Perspective
Hormonal changes also play a role, particularly in women. Research tracking daily urine TMA levels found that FMO3 metabolic capacity drops noticeably around menstruation, even in women who carry only common, “mild” FMO3 variants and who are otherwise symptom-free. In one case involving a woman homozygous for the common position-158/308 variant, enzyme capacity hovered near 90 percent most of the month but plummeted during the days surrounding her period. Healthy controls with no variant copies also showed a dip to roughly 60 to 70 percent capacity around menstruation.7PubMed Central. Transient trimethylaminuria related to menstruation The implication is that sex hormones influence FMO3 regulation in real time, and a person with already-reduced genetic capacity can be tipped into noticeable odor production by a perfectly normal hormonal fluctuation.
Other reported triggers include exercise, stress, fever, and liver disease, all of which can transiently reduce FMO3 output or increase TMA load. Because the margin between “manageable” and “noticeable” depends on both genetic capacity and TMA supply, even small shifts in either direction can cross the threshold.
How Trimethylaminuria Is Diagnosed
Diagnosis relies on measuring the ratio of TMA to TMAO in urine, usually by collecting a sample after a choline-rich meal. If the proportion of free (unconverted) TMA is abnormally high relative to the oxidized TMAO form, that confirms the enzyme is not keeping up. The gold-standard measurement uses NMR spectroscopy, and validation work has confirmed this method is robust enough for routine clinical use.8PubMed. Quality consideration for the validation of urine TMA and TMAO measurement by nuclear magnetic resonance spectroscopy in Fish Odor Syndrome
Genetic testing of the FMO3 gene can identify known mutations and help distinguish between severe and mild forms. However, genetic testing alone is not sufficient for diagnosis because the relationship between specific mutations and actual enzyme performance is not perfectly predictable, and some people with known mild variants only show symptoms transiently. Urine testing after a dietary challenge remains the practical standard, with genetic analysis providing useful supplementary information.
Crucially, the diagnostic process also rules out other causes of unusual body odor, including infections, poor hygiene, and metabolic conditions unrelated to FMO3. The timing of symptom onset and the character of the odor help clinicians distinguish trimethylaminuria from these alternatives.
When the Problem Is Not Metabolic at All
A significant number of people who seek evaluation at genetics clinics for perceived fish-like body odor turn out not to have trimethylaminuria. Instead, they meet the criteria for olfactory reference syndrome, a psychiatric condition in which a person is convinced they emit a foul smell that others can detect, even though objective testing finds no abnormal odor. One study of patients presenting for assessment of unusual body odor found that olfactory reference syndrome could be differentiated from true trimethylaminuria by several features: the age at which concern began (around 28 years on average for the psychiatric condition), the type of odor described (refuse-related rather than specifically fishy), and the presence of other psychiatric diagnoses.9The Journal of Nervous and Mental Disease. The Nose Knows… or Does it? Olfactory Reference Syndrome in Patients Presenting for Assessment of Unusual Body Odor
The overlap between these two conditions is a real clinical problem. Case reports describe patients with no metabolic abnormality who are so certain they have trimethylaminuria that they pursue multiple evaluations and resist psychiatric explanations.10The Journal of Nervous and Mental Disease. Delusional Disorder, Somatic Type: Olfactory Reference Syndrome in a Patient With Delusional Trimethylaminuria Genetics clinics have become an unexpected referral point for olfactory reference syndrome precisely because the internet has made trimethylaminuria widely known. A urine TMA/TMAO test can resolve the question relatively quickly, sparing patients unnecessary dietary restrictions and directing those with a psychiatric basis toward appropriate treatment.
Managing the Condition Day to Day
There is currently no cure for genetic trimethylaminuria, but several strategies can reduce TMA levels enough to bring odor under control or at least make flare-ups less frequent.
- Dietary restriction: Limiting foods high in choline, carnitine, and trimethylamine itself (especially marine fish, eggs, organ meats, and certain legumes) reduces the raw material available for gut bacteria to produce TMA. This is the first-line approach and often the most effective single intervention. The degree of restriction needed varies; some people find they can eat moderate portions of trigger foods on most days but need to avoid them around hormonal shifts or stressful periods.
- Riboflavin (vitamin B2): FMO3 is a flavin-dependent enzyme, meaning it needs riboflavin as a cofactor to function. Supplementation with B2 has been shown to improve both odor and the urinary TMA-to-TMAO ratio, particularly in children with the condition.11PubMed Central. Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin The idea is straightforward: giving the enzyme more of its required cofactor helps squeeze more performance out of whatever functional enzyme remains.
- Activated charcoal: Taking about 1.5 grams of activated charcoal per day for ten days reduced urinary free TMA and normalized TMAO levels in a study of Japanese patients with trimethylaminuria.12PubMed. Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients Charcoal appears to bind TMA in the gut before it can be absorbed.
- Copper chlorophyllin: A chlorophyll derivative taken at about 180 milligrams per day for three weeks also lowered free TMA and raised TMAO in the same study, with effects that seemed to last longer than those of charcoal.13PubMed. Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients
Many people also use acidic soaps and body washes (pH around 5.5) to help neutralize TMA on the skin surface, since TMA is a base. Frequent clothing changes and avoiding synthetic fabrics that trap odor are common practical measures. None of these topical approaches address the underlying metabolic issue, but they reduce the social impact of flare-ups.
The Psychological Toll
Living with trimethylaminuria imposes a burden that goes far beyond the physical symptom. Qualitative research with affected individuals paints a consistent picture: fear, anxiety, and paranoia become daily companions. People describe being hyper-aware of their surroundings and who is standing near them. Unfamiliar environments and strangers provoke intense dread. Many develop distorted thinking patterns, catastrophizing interactions or assuming others are reacting to their odor even when they may not be. Shame, guilt, and damaged self-worth are pervasive, and some individuals reported receiving negative comments about malodor from strangers, friends, family, and coworkers alike. In the most severe cases, sustained negative experiences during childhood or adolescence led to suicidal thoughts.14PubMed Central. Impact of trimethylaminuria on daily psychosocial functioning
This psychological dimension is one reason early and accurate diagnosis matters so much. A person who understands what is happening biologically and has concrete management strategies is in a much better position than someone who spends years confused, ashamed, and unable to explain their situation to others. Some clinicians recommend pairing metabolic management with psychological support, given how deeply the condition can affect social functioning and mental health.15PubMed Central. A review of trimethylaminuria: (fish odor syndrome)
FMO3 Variants and Drug Metabolism
The same FMO3 enzyme that converts TMA also metabolizes a range of medications. This means that the genetic variants responsible for trimethylaminuria can affect how someone processes certain drugs, independent of any odor symptoms. FMO3 oxidizes various pharmaceuticals and xenobiotics, and reduced enzyme activity can shift how quickly or completely those compounds are cleared from the body.16PubMed Central. Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives
A concrete example comes from the antifungal drug voriconazole, widely used in immunocompromised patients. People carrying the common E308G variant of FMO3 showed significantly poorer ability to clear voriconazole from their blood at the start of treatment. They were also more likely to experience adverse reactions including skin problems, visual disturbances, headaches, and liver enzyme elevations. The incidence of visual impairment in the variant group reached 75 percent, compared to significantly lower rates in those with the fully functional enzyme.17Pharmacology. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia This is a reminder that FMO3 genotype has implications beyond body odor, and pharmacogenomic testing for FMO3 variants may eventually become relevant for drug prescribing decisions.
Emerging Therapies Targeting Gut Bacteria
Because TMA is produced by gut microbes before it ever reaches the liver, researchers have increasingly focused on stopping TMA production at its source rather than trying to compensate for a weak enzyme downstream. The key microbial enzyme is called CutC (choline TMA-lyase), which cleaves choline to release TMA in the gut. CutC acts as the bottleneck: block it, and less TMA enters the bloodstream in the first place.18PubMed Central. Gut Microbial Choline TMA-Lyase CutC: From Metabolic Mechanism to a Novel Therapeutic Target for Diseases
The most advanced work in this space has used mechanism-based inhibitors that latch onto the CutC enzyme irreversibly without killing the bacteria that carry it. In animal models, a single oral dose of one such inhibitor lowered plasma TMAO levels for up to three days and reversed diet-induced increases in clot-forming tendency, with no signs of toxicity or bleeding problems.19PubMed Central. Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential Separate work identified another small-molecule inhibitor, betaine aldehyde, that blocks TMA production from choline by both individual bacterial strains and complex gut communities. A crystal structure of how the inhibitor interacts with CutC has opened the door to designing even more targeted molecules.20Journal of the American Chemical Society. Structure-Guided Identification of a Small Molecule That Inhibits Anaerobic Choline Metabolism by Human Gut Bacteria
These approaches are still in early stages and have been developed primarily in the context of cardiovascular disease, where TMAO itself (not TMA) is linked to increased risk. But the logic applies directly to trimethylaminuria: if you can prevent gut bacteria from making TMA in the first place, a person with impaired FMO3 would have far less TMA to worry about. No CutC inhibitor has reached human clinical trials for trimethylaminuria specifically, but the concept is among the most promising avenues for a condition that currently has no pharmacological treatment. Given that dietary restriction asks a lot of patients, and that charcoal and chlorophyllin provide only partial and temporary relief, a once-daily pill that quietly dials down microbial TMA output would represent a genuine shift in what it means to live with this condition.
Why Carrier Frequency Matters More Than You Might Think
Trimethylaminuria is often described as rare, and full-blown cases probably are. But carrier status for the common FMO3 variants that predispose to milder or transient forms is surprisingly widespread. The compound variant at positions 158 and 308, which reduces but does not eliminate enzyme function, was found in 12 to 38 percent of non-African populations across a 13-group survey spanning Europe and East Asia.21PubMed. Flavin-containing monooxygenase 3 polymorphisms in 13 ethnic populations from Europe, East Asia and sub-Saharan Africa: frequency and linkage analysis That means a large fraction of people walking around have mildly reduced FMO3 capacity without ever being aware of it.
Most of the time, the reduced capacity does not matter because FMO3 has enough headroom to handle a normal dietary TMA load. But combine those variants with a high-choline meal, a hormonal dip around menstruation, a bout of liver inflammation, or a medication that competes for FMO3’s attention, and the system can temporarily fall behind. This may explain something that online communities have long discussed: episodes of unexplained body odor in people who do not have a clinical diagnosis. It is possible that some portion of these cases represent transient, subclinical trimethylaminuria in genetically susceptible individuals who never accumulate enough persistent TMA to show up on a standard diagnostic test performed on a random day.
The distinction between “rare genetic disease” and “common enzyme variation with occasional consequences” is not just academic. It affects how seriously clinicians take odor complaints, how aggressively insurance covers testing, and how much research funding flows toward better treatments. The evidence suggests that the full spectrum of trimethylaminuria, from severe lifelong cases to intermittent flares in otherwise unaffected carriers, is considerably broader than the “rare disease” label implies.